<DOC>
	<DOCNO>NCT01493570</DOCNO>
	<brief_summary>Due exploratory nature trial , primary objective confirmatory sense . The study aim - evaluate effect different dos BI 409306 biomarker ass exposure BI 409306</brief_summary>
	<brief_title>Assessment Exposure BI 409306 Cerebrospinal Fluid ( CSF ) Relative Plasma Well Evaluation Effect Different Doses BI 409306 cGMP ( Cyclic Guanosine Monophosphate ) Levels CSF Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign 10 minute supine position ( BP ( blood pressure ) , PR ( pulse rate ) , BT ( body temperature ) ) , 12lead ECG ( electrocardiogram ) , clinical laboratory test 2 . Age =21 Age =50 year 3 . BMI =18.5 BMI =29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal consider investigator clinical relevant 2 . Abnormal value PT ( Prothrombin Time ) ( , aPTT ( Partial Thromboplastin Time ) trombocytes consider investigator clinically relevant 3 . Any evidence clinically relevant concomitant disease 4 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 5 . Surgery gastrointestinal tract ( except appendectomy ) 6 . Diseases central nervous system ( include limit kind seizure , stroke psychiatric disorder ) 7 . History relevant orthostatic hypotension , faint spell blackout . 8 . Chronic relevant acute infection 9 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 10 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration 11 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 12 . Participation another trial investigational drug within two month prior administration trial 13 . Smoker , consume 5 cigarette per day 14 . Inability refrain smoke trial day 15 . Alcohol abuse ( 20 g/day ) : 2 units/day ( 14 units/week ) 16 . Drug abuse 17 . Blood donation ( 100 mL within four week prior administration trial ) 18 . Excessive physical activity ( within one week prior administration trial ) 19 . Any laboratory value outside reference range clinical relevance 20 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTcF interval &gt; 450 m ) 21 . Inability understand comply protocol requirement restriction dietary regimen trial site 22. additional risk factor TdP ( Torsades de point ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) 23 . Male subject agree minimize risk female partner become pregnant first dose day three month study completion . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female ( intrauterine device spermicide , hormonal contraceptive since least two month )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>